Joint MHRA/DIA Excellence in Pharmacovigilance: Clinical Trials and Post-Marketing

The 5 days of training include a comprehensive overview of the core processes and systems in place and the latest news on the international harmonisation and standardisation activities in pharmacovigilance.

Back to Agenda

Topic 2 Session 9 continued: Audits and Inspections in Pharmacovigilance – Industry Perspective

Speaker(s)

Audits and Inspections in Pharmacovigilance - Industry Perspective

Jonathan Rowell

Janssen Pharmaceutical Research & Development Quality & Compliance, United Kingdom

Director Regulatory Compliance